Larvol Delta - Eblasakimab-Monthly-Dosing-Shows-Potential-for-BestInClass-Therapy-in-Positive-Phase-2b-Study-in-Atopic-Dermatitis

eblasakimab (ASLAN004) - ASLAN Pharma, Zenyaku Holdings

https://www.globenewswire.com/news-release/2023/07/06/2700249/0/en/Eblasakimab-Monthly-Dosing-Shows-Potential-for-Best-In-Class-Therapy-in-Positive-Phase-2b-Study-in-Atopic-Dermatitis.html

Jul 6, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next